Genetics and cancer #activesurveillance #ProstateCancer #ASPI #Gleason6 #PSA

Low Gleason Score (6 or 7) + High PSA? | Prostate Cancer | Mark Scholz, MD | PCRIПодробнее

Gleason 6 #ProstateCancer 101 | #MarkScholzMD #AlexScholz #PCRIПодробнее

How safe is a Gleason 6?Подробнее

Active Surveillance in Favorable Intermediate-Risk Prostate CancerПодробнее

Somatic testing | #activesurveillance #ProstateCancer #ASPI #Gleason6 #PSAПодробнее

Active Surveillance Who is the Right Patient and What is the Right ProtocolПодробнее

Prostate Cancer Active Surveillance Protocol for Gleason 6 CancerПодробнее

3+4=7 #ProstateCancer | Active Surveillance vs. Focal Therapy | #MarkScholzMD #AlexScholz #PCRIПодробнее

Active Surveillance #activesurveillance #ProstateCancer #ASPI #Gleason6 #PSAПодробнее

PI-RADS, Active Surveillance Protocols for 3+3=6 & 3+4=7, & Genomic/Genetics Tests | Mark Scholz, MDПодробнее

Active Surveillance of Prostate Cancer with Yushen Qian, MDПодробнее

Genetic Markers #activesurveillance #ProstateCancer #ASPI #Gleason6 #PSAПодробнее

Decipher, SelectMDx, and 4K Score in Active Surveillance & Intermediate Prostate Cancer | PCRIПодробнее

Active Surveillance Results and Implications of Prospective StudiesПодробнее

Active surveillance in localized prostate cancerПодробнее

Low Risk (Gleason 3+3=6) & Intermediate Risk (Gleason 3+4=7) Prostate Cancer Q+A | PCRI #13Подробнее

The Fear of Cancer & Choosing Active Surveillance | Ask a Prostate Expert, Mark Scholz, MDПодробнее

Molecular testing | #activesurveillance #ProstateCancer #ASPI #Gleason6Подробнее

Active Surveillance for Prostate CancerПодробнее

Urine-based markers and PSMA | #activesurveillance #ProstateCancer #ASPI #Gleason6Подробнее